Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

Individuals on SSRIs still exhibit depressive symptoms

Even people who show a clear treatment response with antidepressant medications continue to experience symptoms like insomnia, sadness and decreased concentration, researchers at UT Southwestern Medical Center have found after analyzing data from the largest study on the treatment of depression.

25 Apr 2011

Severely obese adolescents no more likely to be depressed

According to a new study, severely obese adolescents are no more likely to be depressed than normal weight peers. The study, which has been released online in the Journal of Adolescent Health, did find that white adolescents may be somewhat more vulnerable to psychological effects of obesity.

22 Apr 2011

Study underscores need for more targeted antidepressant therapies to decrease depressive symptoms

21 Apr 2011

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Neuralstem, Inc. (NYSE Amex: CUR) announced it has signed a Memorandum of Understanding with BaYi Brain Hospital in Beijing, China.

21 Apr 2011

Parks and green environments impact social, psychological and physical health outcomes

Research shows that a walk in the park is more than just a nice way to spend an afternoon. It's an essential component for good health, according to University of Illinois environment and behavior researcher Frances "Ming" Kuo.

20 Apr 2011

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.12 in the fourth quarter of fiscal 2011.

19 Apr 2011

Major depression linked to premature aging of immune cells: Study

Certain cases of major depression are associated with premature aging of immune cells, which may make people more susceptible to other serious illness, according to findings from a new UCSF-led study.

6 Apr 2011

Vanda to initiate tasimelteon Phase IIb/III clinical trial in Major Depressive Disorder

Vanda Pharmaceuticals Inc. today announced its plans to initiate a Phase IIb/III clinical trial of tasimelteon in patients with Major Depressive Disorder (MDD). The trial is expected to begin during the second half of 2011. Tasimelteon is currently being evaluated in Phase III clinical trials for the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals without light perception.

31 Mar 2011

AssureRx closes $11 million Series B financing

AssureRx Health, Inc. today announced the closing of an $11 million Series B financing. The personalized medicine company, which provides clinically-relevant information to help physicians select the right drug and the right dose for individual neuropsychiatric patients, will use the funds to expand direct sales and marketing for its first product, GeneSightRx®, and for second generation product development activities.

25 Mar 2011

Brain's pleasure and reward circuitry gets a big boost after a sleepless night

A sleepless night can make us cranky and moody. But a lesser known side effect of sleep deprivation is short-term euphoria, which can potentially lead to poor judgment and addictive behavior, according to new research from the University of California, Berkeley.

24 Mar 2011

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has enrolled 33 percent of the total projected patients required for its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

24 Mar 2011

Clinical depression can exacerbate Knee osteoarthritis symptoms in elder patients

Clinical depression can exacerbate the symptoms of knee arthritis beyond what is evident on X-rays, according to a new study from the Journal of Bone and Joint Surgery.

17 Mar 2011

Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder

Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) trial is a phase 2b/3a clinical trial designed to assess the safety and efficacy of EB-1010, a novel serotonin-preferring triple reuptake inhibitor.

14 Mar 2011

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Neuralstem, Inc. announced that the first subject was dosed yesterday in a Phase Ia trial to evaluate the safety of its drug, NSI-189, which is being developed for the treatment of major depressive disorder and other psychiatric indications. NSI-189 is the lead compound in Neuralstem's neurogenerative small molecule drug platform. This phase of the trial is in healthy volunteers and seeks to determine the maximum tolerated single dose.

2 Mar 2011

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine as adjunctive therapy in major depressive disorder.

28 Feb 2011

Forest Labs enters definitive merger agreement to acquire Clinical Data

Forest Laboratories, Inc. and Clinical Data, Inc. today announced that they have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics, for $30.00 per share in cash plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones related to Viibryd.

22 Feb 2011

Research: Blood and hormone level in saliva can reveal burnout symptoms

Your blood and the level of a hormone in your spit could reveal if you're on the point of burnout, according to research undertaken by Dr. Sonia Lupien and Robert-Paul Juster of the Centre for Studies on Human Stress of Louis-H. Lafontaine Hospital and the University of Montreal.

22 Feb 2011

Grief after loss of a significant other may become a disease

In the current issue of Psychotherapy and Psychosomatics, a group of French investigators headed by Guy Chouinard presents data that indicate that grief after the loss of a significant other may become a disease. One issue facing the DSM-V in the revision of the criteria for major depressive disorder (MDD) concerns bereavement criterion E, which often leads to exclusion from major depressive episode (MDE).

16 Feb 2011

WINCS detects and measures serotonin levels in brain through deep brain stimulation

Mayo Clinic researchers have concluded that, through deep brain stimulation, a Wireless Instantaneous Neurotransmitter Concentration System (WINCS) can detect and measure serotonin levels in the brain. The findings suggest that in the future such measurements of serotonin may help establish a therapeutic mechanism of deep brain stimulation for psychiatric disease.

16 Feb 2011

New study finds peer support greatly reduces symptoms of depression

Peer support offers promise as an effective, low-cost tool for fighting depression, a new study by the VA Ann Arbor Healthcare System and University of Michigan Health System finds.

16 Feb 2011

Major Depressive Disorder News and Research

Further Reading

Individuals on SSRIs still exhibit depressive symptoms

Severely obese adolescents no more likely to be depressed

Study underscores need for more targeted antidepressant therapies to decrease depressive symptoms

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Parks and green environments impact social, psychological and physical health outcomes

Forest Labs fourth quarter net sales increase 9.7% to $1,091.9 million

Major depression linked to premature aging of immune cells: Study

Vanda to initiate tasimelteon Phase IIb/III clinical trial in Major Depressive Disorder

AssureRx closes $11 million Series B financing

Brain's pleasure and reward circuitry gets a big boost after a sleepless night

Rexahn completes 33% of 300 patient enrollment in Serdaxin Phase IIb clinical trial for major depressive disorder

Clinical depression can exacerbate Knee osteoarthritis symptoms in elder patients

Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder

Neuralstem announces initiation of NSI-189 Phase Ia trial for major depressive disorder

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

Forest Labs enters definitive merger agreement to acquire Clinical Data

Research: Blood and hormone level in saliva can reveal burnout symptoms

Grief after loss of a significant other may become a disease

WINCS detects and measures serotonin levels in brain through deep brain stimulation

New study finds peer support greatly reduces symptoms of depression

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News